Final NIH Conflict-Of-Interest Rule Reinforces Industry Consulting Ban
This article was originally published in The Gray Sheet
Executive Summary
The National Institutes of Health reinforced its prohibition for staff on outside consulting with device, pharmaceutical or biotechnology companies with the release of its final conflict-of-interest regulation Aug. 25